A Phase 2/3 interventional study of Voriconazole in Aspergillosis, sponsored by Pfizer. Completed at 18 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-01-20.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.
Among the 17 studies testing voriconazole in Aspergillosis, this one is the 4th largest by enrollment, is the only one that started in 2005, is the only one in phase 2/3, and was the 5th registered.
134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.
Browse Aspergillosis studies →None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →
Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 4
First in 1997; this study’s year is marked. 1 started in 2005.
This study's enrollment of 48 is close to the median of 47 across 75 interventional studies indexed under Aspergillosis.
Median enrollment 24 across the 17 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
11 studies in Aspergillosis by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Aspergillosis by Pfizer, this one is the only one that started in 2005, is one of 2 in phase 2/3, and was the 2nd registered.
Pfizer’s Aspergillosis studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing voriconazole in Aspergillosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 11 in Aspergillosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e. chronic necrotizing pulmonary
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Voriconazole
Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response. Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours
Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis
Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline; partial response: reduction in diameter ≥ 50 percent on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.
Time frame: at 6 months of treatment
Number of Subjects With Successful Global Outcome at Month 3 and End of Treatment: Chronic Bronchopulmonary Aspergillosis
Successful global outcome: composite assessment of radiological and mycological responses; defined as complete (resolution of radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline) or partial (reduction in diameter ≥ 50 percent on chest TDM or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion) radiological response and mycological eradication after 3 months of treatment and after 9 or 12 months (in case of extension of treatment period beyond 6 months); no success=criteria not met. Assessment determined by DRC.
Time frame: Month 3 and End of Treatment (Month 9 or Month 12)
Number of Subjects With Successful Global Outcome at 6 Months: Chronic Necrotizing Pulmonary Aspergillosis (CNPA) and Tracheo-bronchial Aspergillosis
Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to the aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.
Time frame: at 6 months of treatment
Number of Subjects With Successful Global Outcome at 6 Months: Complex Aspergilloma
Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to the aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.
Time frame: at 6 months of treatment
Change From Baseline in Respiratory Clinical Signs and Symptoms on Visual Analog Scales (VAS)
Subject assessment of improvement of respiratory clinical signs and symptoms as indicated by the subject placing a mark on a 10 cm VAS scored 0 (better state of health) to 100 (poor state of health) for cough, dyspnea, sputum, hemoptysis, chest tightness, and nocturnal awakening. Change from baseline: mean of (value of scores on scale at treatment visit minus baseline value).
Time frame: Baseline, Month 3, and Month 6, Month 9, or Month 12 [EOT], and End of study ([EOS] EOT + 6 months)
Number of Subjects With Relapse
Relapse: any proven reappearance of pulmonary aspergillosis during the follow-up period, following a successful global outcome at EOT, and defined as a deterioration of clinical signs and symptoms, confirmed radiologically (chest \[TDM\] and or endoscopy) and mycologically (histology and or culture and or serology).
Time frame: During the 6 months following EOT (EOT + 3 months, EOT + 6 months)
Time to Relapse After EOT
Time (months) to relapse: any proven reappearance of pulmonary aspergillosis during the follow-up period, following a successful global outcome at EOT, and defined as a deterioration of clinical signs and symptoms, confirmed radiologically (chest \[TDM\] and or endoscopy) and mycologically (histology and or culture and or serology).
Time frame: During the 6 months following EOT (EOT + 3 months, EOT + 6 months)
Global Survival: Number of Subjects With an Outcome of Death
Number of subjects with an outcome of death (adverse event with a fatal outcome) through end of study.
Time frame: Baseline through EOS (EOT + 6 months)
Change From Baseline in Quality of Life (QOL): St. George's Hospital Respiratory Questionnaire
Subject administered questionnaire to measure improvement in QOL; 50 questions exploring 3 different areas: symptoms, impact on activity profile (activity), and impact on daily life (impacts). Each item in an area is weighted based on empirical data; scores range from lowest possible weight 0 to highest possible weight 100. Scores for each section and total score calculated using score calculation algorithms with higher scores indicating poor health. Change from baseline: mean of (value of scores on scale at treatment visit minus baseline value).
Time frame: Baseline, Month 3, and Month 6, Month 9, or Month 12 [EOT], and EOS (EOT + 6 months)
Number of Subjects With Complete or Partial Radiological Response
Radiological response: based on chest TDM except for tracheo-bronchialaspergillosis which was assessed by bronchoscopy. Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest TDM or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.
Time frame: Month 3, and Month 6, Month 9, or Month 12 [EOT]
Number of Subjects With Mycological Response of Eradication
Mycological response: eradication: absence of aspergillus species (spp) in bronchopulmonary samples: sputum, bronchial aspirate or bronchoalveolar lavage (BAL) (negative direct examination \[exam\] and negative culture), and negative histological exam when available; persistence (no eradication): presence of aspergillus spp in any relevant bronchopulmonary samples. Not done (presumed eradication): case reviewed by DRC for any mycological exams not performed to assess if case should constitute presumed eradication (no sputum due to clinical improvement).
Time frame: Month 3, and Month 6, Month 9, or Month 12 [EOT]
Number of Subjects With Complete or Partial Serological Response
Serological response: normalization (complete response) defined as return to normal values (≤ 1 arc); partial response defined as significant decrease but not complete (decrease of 2 or more arcs compared to baseline). Complete or partial response summarized as Improvement; based on arc values at visit compared to arc values at baseline (inclusion).
Time frame: Month 3, and Month 6, Month 9, or Month 12 [EOT]
18 active centers in France; planned recruitment of 48 minimally immunocompromised or non-immunocompromised subjects with chronic bronchopulmonary aspergillosis.
| Milestone | Voriconazole |
|---|---|
| Started | 48 |
| Completed | 26 |
| Not completed | 22 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Adverse event | 9 |
| Withdrew: Death | 4 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 2 |
| Milestone | Voriconazole |
|---|---|
| Started | 26 |
| Completed | 23 |
| Not completed | 3 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Reason unspecified | 1 |
Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline; partial response: reduction in diameter ≥ 50 percent on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.
| participants | Voriconazole |
|---|---|
| Success | 13 |
| No success | 28 |
Successful global outcome: composite assessment of radiological and mycological responses; defined as complete (resolution of radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline) or partial (reduction in diameter ≥ 50 percent on chest TDM or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion) radiological response and mycological eradication after 3 months of treatment and after 9 or 12 months (in case of extension of treatment period beyond 6 months); no success=criteria not met. Assessment determined by DRC.
| participants | Voriconazole |
|---|---|
| Month 3 success=yes | 12 |
| Month 3 success=no | 24 |
| Month 3 success=missing values | 5 |
| EOT [LVA] success=yes | 18 |
| EOT [LVA] success=no | 23 |
Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to the aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.
| participants | Voriconazole |
|---|---|
| Success | 10 |
| No success | 9 |
Successful global outcome: composite assessment of radiological and mycological responses; defined as complete or partial radiological response and mycological eradication (absence of aspergillus); no success=criteria not met. Assessment was determined by the Data Review Committee (DRC). Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to the aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest tomodensitometry (TDM) or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.
| paticipants | Voriconazole |
|---|---|
| Success | 3 |
| No success | 19 |
Subject assessment of improvement of respiratory clinical signs and symptoms as indicated by the subject placing a mark on a 10 cm VAS scored 0 (better state of health) to 100 (poor state of health) for cough, dyspnea, sputum, hemoptysis, chest tightness, and nocturnal awakening. Change from baseline: mean of (value of scores on scale at treatment visit minus baseline value).
| scores on scale | Voriconazole |
|---|---|
| Cough Month 3 (n=30) | -15.80 ± 33.40 |
| Cough Month 6 (n=27) | -19.63 ± 35.48 |
| Cough Month 9 (n=20) | -17.45 ± 43.01 |
| Cough Month 12 (n=16) | -30.13 ± 37.01 |
| Cough EOS (n=20) | -13.65 ± 41.31 |
| Dyspnea Month 3 (n=30) | -2.67 ± 24.22 |
| Dyspnea Month 6 (n=27) | -4.22 ± 25.16 |
| Dyspnea Month 9 (n=20) | -1.40 ± 24.66 |
| Dyspnea Month 12 (n=16) | -8.69 ± 25.15 |
| Dyspnea EOS (n=20) | 1.75 ± 31.30 |
| Sputum Month 3 (n=30) | -8.03 ± 27.44 |
| Sputum Month 6 (n=28) | -14.86 ± 37.11 |
| Sputum Month 9 (n=21) | -12.62 ± 37.35 |
| Sputum Month 12 (n=17) | -26.47 ± 26.59 |
| Sputum EOS (n=21) | -13.67 ± 36.20 |
| Hemoptysis Month 3 (n=30) | -2.13 ± 28.05 |
| Hemoptysis Month 6 (n=28) | 5.11 ± 27.41 |
| Hemoptysis Month 9 (n=21) | -4.52 ± 30.32 |
| Hemoptysis Month 12 (n=16) | -8.31 ± 31.44 |
| Hemoptysis EOS (n=21) | 1.14 ± 20.72 |
| Chest tightness Month 3 (n=30) | 0.03 ± 37.85 |
| Chest tightness Month 6 (n=28) | 0.86 ± 29.83 |
| Chest tightness Month 9 (n=21) | -1.52 ± 33.03 |
| Chest tightness Month 12 (n=17) | -9.29 ± 31.27 |
| Chest tightness EOS (n=20) | -4.00 ± 22.31 |
| Nocturnal awakening Month 3 (n=30) | 0.57 ± 29.33 |
| Nocturnal awakening Month 6 (n=28) | -2.86 ± 36.84 |
| Nocturnal awakening Month 9 (n=21) | -2.40 ± 31.13 |
| Nocturnal awakening Month 12 (n=16) | 4.00 ± 31.45 |
| Nocturnal awakening EOS (n=21) | 5.29 ± 41.96 |
| Mean VAS Month 3 (n=30) | -4.67 ± 18.29 |
| Mean VAS Month 6 (n=27) | -5.99 ± 20.82 |
| Mean VAS Month 9 (n=20) | -7.16 ± 24.31 |
| Mean VAS Month 12 (n=15) | -15.87 ± 20.67 |
| Mean VAS EOS (n=19) | -6.58 ± 20.43 |
Relapse: any proven reappearance of pulmonary aspergillosis during the follow-up period, following a successful global outcome at EOT, and defined as a deterioration of clinical signs and symptoms, confirmed radiologically (chest \[TDM\] and or endoscopy) and mycologically (histology and or culture and or serology).
No measurements were reported for this outcome.
Time (months) to relapse: any proven reappearance of pulmonary aspergillosis during the follow-up period, following a successful global outcome at EOT, and defined as a deterioration of clinical signs and symptoms, confirmed radiologically (chest \[TDM\] and or endoscopy) and mycologically (histology and or culture and or serology).
No measurements were reported for this outcome.
Number of subjects with an outcome of death (adverse event with a fatal outcome) through end of study.
| participants | Voriconazole |
|---|---|
| Global Survival: Number of Subjects With an Outcome of Death | 5 (0.725 to 0.976) |
Subject administered questionnaire to measure improvement in QOL; 50 questions exploring 3 different areas: symptoms, impact on activity profile (activity), and impact on daily life (impacts). Each item in an area is weighted based on empirical data; scores range from lowest possible weight 0 to highest possible weight 100. Scores for each section and total score calculated using score calculation algorithms with higher scores indicating poor health. Change from baseline: mean of (value of scores on scale at treatment visit minus baseline value).
| scores on scale | Voriconazole |
|---|---|
| Symptoms Month 3 (n=35) | -5.50 ± 22.53 |
| Symptoms Month 6 (n=29) | -3.32 ± 7.37 |
| Symptoms Month 9 (n=19) | 0.96 ± 29.78 |
| Symptoms Month 12 (n=17) | -2.72 ± 23.80 |
| Symptoms EOS (n=23) | -6.84 ± 23.53 |
| Activity Month 3 (n=31) | -4.15 ± 17.72 |
| Activity Month 6 (n=28) | -9.43 ± 17.30 |
| Activity Month 9 (n=18) | -0.03 ± 18.04 |
| Activity Month 12 (n=18) | -5.88 (-10.98 to -0.78) |
| Activity EOS (n=23) | -8.06 (-14.58 to -1.54) |
| Impacts Month 3 (n=33) | -6.72 (-12.42 to -1.03) |
| Impacts Month 6 (n=28) | -8.41 (-15.22 to -1.61) |
| Impacts Month 9 (n=20) | -3.78 (-14.72 to 7.16) |
| Impacts Month 12 (n=18) | -7.97 (-16.49 to 0.55) |
| Impacts EOS (n=21) | -7.93 (-13.46 to -2.40) |
| Total Month 3 (n=35) | -5.70 (-10.60 to -0.81) |
| Total Month 6 (n=30) | -8.39 (-14.02 to -2.76) |
| Total Month 9 (n=20) | -1.87 (-11.26 to 7.51) |
| Total Month 12 (n=18) | -6.63 (-12.97 to -0.28) |
| Total EOS (n=24) | -8.19 (-12.41 to -3.96) |
Radiological response: based on chest TDM except for tracheo-bronchialaspergillosis which was assessed by bronchoscopy. Complete response: resolution of all radiographic and or bronchoscopic abnormalities attributable to aspergillosis present at baseline; partial response: reduction in diameter ≥ 50% on chest TDM or regressed lesion on endoscopy witnessed by 2 different operators without any new lesion.
| participants | Voriconazole |
|---|---|
| Month 3 Complete response | 4 |
| Month 3 Partial response | 9 |
| EOT [LVA] Complete response | 6 |
| EOT [LVA] Partial response | 14 |
Mycological response: eradication: absence of aspergillus species (spp) in bronchopulmonary samples: sputum, bronchial aspirate or bronchoalveolar lavage (BAL) (negative direct examination \[exam\] and negative culture), and negative histological exam when available; persistence (no eradication): presence of aspergillus spp in any relevant bronchopulmonary samples. Not done (presumed eradication): case reviewed by DRC for any mycological exams not performed to assess if case should constitute presumed eradication (no sputum due to clinical improvement).
| participants | Voriconazole |
|---|---|
| Month 3 Eradication | 29 |
| Month 3 Persistence | 3 |
| Month 3 Not done (presume eradication) | 3 |
| Month 6 Eradication | 26 |
| Month 6 Not done (presume eradication) | 6 |
| Month 9 Eradication | 14 |
| Month 9 Not done (presume eradication) | 7 |
| Month 12 Eradication | 15 |
| Month 12 Not done (presume eradication) | 2 |
Serological response: normalization (complete response) defined as return to normal values (≤ 1 arc); partial response defined as significant decrease but not complete (decrease of 2 or more arcs compared to baseline). Complete or partial response summarized as Improvement; based on arc values at visit compared to arc values at baseline (inclusion).
| participants | Voriconazole |
|---|---|
| Month 3 Improvement | 10 |
| Month 6 Improvement | 14 |
| Month 9 Improvement | 9 |
| Month 12 Improvement | 8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voriconazole | — | 21/48 (43.8%) | 33/48 (68.8%) |
| Event | Voriconazole |
|---|---|
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 5/48 |
| General physical health deteriorationGeneral disorders | 2/48 |
| BronchitisInfections and infestations | 2/48 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/48 |
| Abdominal painGastrointestinal disorders | 1/48 |
| Abdominal pain upperGastrointestinal disorders | 1/48 |
| ConstipationGastrointestinal disorders | 1/48 |
| VomitingGastrointestinal disorders | 1/48 |
| CholecystitisHepatobiliary disorders | 1/48 |
| Bronchitis haemophilusInfections and infestations | 1/48 |
| Event | Voriconazole |
|---|---|
| Visual impairmentEye disorders | 9/48 |
| BronchitisInfections and infestations | 9/48 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 7/48 |
| Vision blurredEye disorders | 6/48 |
| InsomniaPsychiatric disorders | 6/48 |
| Photosensitivity reactionSkin and subcutaneous tissue disorders | 6/48 |
| ChillsGeneral disorders | 4/48 |
| Gamma-glutamyltransferase increasedInvestigations | 4/48 |
| ConstipationGastrointestinal disorders | 3/48 |
| NauseaGastrointestinal disorders | 3/48 |
| Age Continuous(years) | Voriconazole |
|---|---|
| Mean | 57.27 ± 13.85 |
| Sex: Female, Male(Participants) | Voriconazole |
|---|---|
| Female | 19 |
| Male | 29 |
The record gives a start of Jul 2005, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole